Re-engineering clostridial neurotoxins for the treatment of chronic pain: Current status and future prospects

BioDrugs

Volumn 24, Issue 3, 2010, Pages 173-182

  Pickett, Andy ^a  

^a IPSEN   (France)

Author keywords

[No Author keywords available]

Indexed keywords

AZZALURE; BOCOUTURE; BOTULINUM TOXIN A; BOTULINUM TOXIN B; CALCITONIN GENE RELATED PEPTIDE; NEUROPEPTIDE; PLACEBO; SNARE PROTEIN; SUBSTANCE P; SYNAPTOBREVIN; SYNAPTOSOMAL ASSOCIATED PROTEIN 25; SYNTAXIN; UNCLASSIFIED DRUG;

ACETYLCHOLINE RELEASE; ANALGESIC ACTIVITY; CERVICAL DYSTONIA; CHRONIC DAILY HEADACHE; CHRONIC PAIN; CLINICAL TRIAL; CLOSTRIDIUM BOTULINUM; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; HEADACHE; HEMIPLEGIA; HUMAN; ISCHIALGIA; LOW BACK PAIN; MIGRAINE; MOTONEURON; MUSCLE RELAXATION; MYOFASCIAL PAIN; NEUROMUSCULAR DISEASE; NEUROMUSCULAR SYNAPSE; NEUROPATHIC PAIN; NEUROTRANSMITTER RELEASE; NOCICEPTIVE RECEPTOR; PELVIS PAIN SYNDROME; PRIORITY JOURNAL; REVIEW; SHOULDER PAIN; SPASTIC HEMIPLEGIA; STRUCTURE ACTIVITY RELATION; TENSION HEADACHE;

ANALGESICS; ANIMALS; BOTULINUM TOXIN TYPE A; BOTULINUM TOXINS; CHRONIC DISEASE; HUMANS; NEUROMUSCULAR JUNCTION; NEUROTOXINS; PAIN; PROTEIN ENGINEERING; SIGNAL TRANSDUCTION; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 77952473041     PISSN: 11738804     EISSN: 1179190X     Source Type: Journal    
DOI: 10.2165/11534510-000000000-00000     Document Type: Review

References (96)

1. Turton K, Chaddock JA, Acharya KR. Botulinum and tetanus neurotoxins: structure, function and therapeutic utility. Trends Biochem Sci 2002 Nov;27(11):552-8
2. Lacy DB, Stevens RC. Sequence homology and structural analysis of the clostridial neurotoxins. J Mol Biol 1999 Sep. 3;291(5):1091-104
3. Kurazono H, Mochida S, Binz T, et al. Minimal essential domains specifying toxicity of the light chains of tetanus toxin and botulinum neurotoxin type A. J Biol Chem 1992 Jul. 25;267(21):14721-9
4. Chaddock JA, Marks PM. Clostridial neurotoxins: structure-function led design of new therapeutics. Cell Mol Life Sci 2006 Mar;63(5):540-51
5. Jabbari B. Botulinum neurotoxins in the treatment of refractory pain. Nat Clin Pract Neurol 2008 Dec;4(12):676-85
6. Byers M, Bonica JJ. Peripheral pain mechanisms and nociceptor plasticity. In: Loeser JD, Butler SH, Chapman CR, editors. Bonica's management of pain. Baltimore (MD): Lippincott Williams and Wilkins, 2001: 26-72
7. Meyer RA, Campbell JN, Raja SN. Peripheral neural mechanisms of nociception. In: Wall PD, Melzack R, editors. Textbook of pain. 3rd ed. Edinburgh: Churchill Livingstone, 1994: 13-44
8. Stucky CL, Gold MS, Zhang X. Mechanismsof pain. Proc Natl Acad Sci U SA 2001 Oct. 9;98(21):11845-6
9. Treede RD, Jensen TS, Campbell JN, et al. Neuropathic pain: redefinition and a grading system for clinical and research purposes. Neurology 2008 Apr. 29;70(18):1630-5
10. Robinson DR, Gebhart GF. Inside information: the unique features of visceral sensation. Mol Interv 2008 Oct;8(5):242-53
11. Sycha T, Kranz G, Auff E, et al. Botulinum toxin in the treatment of rare head and neck pain syndromes: a systematic review of the literature. J Neurol 2004 Feb; 251 Suppl. 1: I19-30
12. Jeynes LC, Gauci CA. Evidence for the use of botulinum toxin in the chronic pain setting-a review of the literature. Pain Pract 2008 Jul-Aug;8(4):269-76
13. Greene P, Kang U, Fahn S, et al. Double-blind, placebo-controlled trial of botulinum toxin injections for the treatment of spasmodic torticollis. Neurology 1990 Aug;40(8):1213-8
14. Poewe W, Deuschl G, Nebe A, et al. What is the optimal dose of botulinum toxin A in the treatment of cervical dystonia? Results of a double blind, placebo controlled, dose ranging study using Dysport. German Dystonia Study Group. J Neurol Neurosurg Psychiatry 1998 Jan;64(1):13-7
15. Truong D, Duane DD, Jankovic J, et al. Efficacy and safety of botulinum typeA toxin (Dysport) in cervical dystonia: results of the first US randomized, double-blind, placebo-controlled study. Mov Disord 2005 Jul;20(7):783-91
16. Lew MF, Adornato BT, Duane DD, et al. Botulinum toxin type B: a doubleblind, placebo-controlled, safety and efficacy study in cervical dystonia. Neurology 1997 Sep;49(3):701-7
17. Brin MF, Lew MF, Adler CH, et al. Safety and efficacy of NeuroBloc (botulinum toxin type B) in type A-resistant cervical dystonia. Neurology 1999 Oct. 22;53(7):1431-8
18. Brashear A, Lew MF, Dykstra DD, et al. Safety and efficacy of NeuroBloc (botulinum toxin type B) in type A-responsive cervical dystonia. Neurology 1999 Oct. 22;53(7):1439-46
19. Brans JW, Lindeboom R, Snoek JW, et al. Botulinum toxin versus trihexyphenidyl in cervical dystonia: a prospective, randomized, double-blind controlled trial. Neurology 1996 Apr;46(4):1066-72
20. Saper JR, Mathew NT, Loder EW, et al. A double-blind, randomized, placebo-controlled comparison of botulinum toxin type a injection sites and doses in the prevention of episodic migraine. Pain Med 2007 Sep;8(6):478-85
21. Elkind AH, O'Carroll P, Blumenfeld A, et al. A series of three sequential, randomized, controlled studies of repeated treatments with botulinum toxin type A for migraine prophylaxis. J Pain 2006 Oct;7(10):688-96
22. Aurora SK, Gawel M, Brandes JL, et al. Botulinum toxin type a prophylactic treatment of episodic migraine: a randomized, double-blind, placebocontrolled exploratory study. Headache 2007 Apr;47(4):486-99
23. Relja M, Poole AC, Schoenen J, et al. A multicentre, double-blind, randomized, placebo-controlled, parallel group study of multiple treatments of botulinum toxin type A (BoNTA) for the prophylaxis of episodic migraine headaches. Cephalalgia 2007 Jun;27(6):492-503
24. Silberstein S, Mathew N, Saper J, et al. Botulinum toxin type A as a migraine preventive treatment. For the BOTOX Migraine Clinical Research Group. Headache 2000 Jun;40(6):445-50
25. Evers S, Vollmer-Haase J, Schwaag S, et al. Botulinum toxin A in the prophylactic treatment of migraine -a randomized, double-blind, placebocontrolled study. Cephalalgia 2004 Oct;24(10):838-43
26. Vo AH, Satori R, Jabbari B, et al. Botulinum toxin type-a in the prevention of migraine: a double-blind controlled trial. Aviat Space Environ Med 2007 May; 78 (5 Suppl.): B113-8
27. Blumenfeld AM, Schim JD, Chippendale TJ. Botulinum toxin type A and divalproex sodium for prophylactic treatment of episodic or chronic migraine. Headache 2008 Feb;48(2):210-20
28. Freitag FG, Diamond S, Diamond M, et al. Botulinum toxin type A in the treatment of chronic migraine without medication overuse. Headache 2008 Feb;48(2):201-9
29. Dodick DW, Smith TR, Becker WJ, et al. Botulinum neurotoxin type A for treatment of chronic migraine: PREEMPT 2 trial double-blind phase [abstract no. PO46]. Cephalagia 2009; 29 Suppl. 1
30. Aurora SK, Schim JD, Cutrer FM, et al. Botulinum neurotoxin type A for treatment of chronic migraine: PREEMPT 1 trial double-blind phase [abstract no. PO45]. Cephalagia 2009; 29 Suppl. 1
31. Ondo WG, Vuong KD, Derman HS. Botulinum toxin A for chronic daily headache: a randomized, placebo-controlled, parallel design study. Cephalalgia 2004 Jan;24(1):60-5
32. Mathew NT, Frishberg BM, Gawel M, et al. Botulinum toxin type A (BOTOX) for the prophylactic treatment of chronic daily headache: a randomized, double-blind, placebo-controlled trial. Headache 2005 Apr;45(4):293-307
33. Dodick DW, Mauskop A, Elkind AH, et al. Botulinum toxin type a for the prophylaxis of chronic daily headache: subgroup analysis of patients not receiving other prophylactic medications: a randomized double-blind, placebo-controlled study. Headache 2005 Apr;45(4):315-24
34. Silberstein SD, Stark SR, Lucas SM, et al. Botulinum toxin type A for the prophylactic treatment of chronic daily headache: a randomized, double-blind, placebo-controlled trial. Mayo Clin Proc 2005 Sep;80(9):1126-37
35. Rollnik JD, Tanneberger O, Schubert M, et al. Treatment of tension-type headache with botulinum toxin type A: a double-blind, placebo-controlled study. Headache 2000 Apr;40(4):300-5
36. Schmitt WJ, Slowey E, Fravi N, et al. Effect of botulinum toxin A injections in the treatment of chronic tension-type headache: a double-blind, placebocontrolled trial. Headache 2001 Jul-Aug;41(7):658-64
37. Padberg M, de Bruijn SF, de Haan RJ, et al. Treatment of chronic tension-type headache with botulinum toxin: a double-blind, placebo-controlled clinical trial. Cephalalgia 2004 Aug;24(8):675-80
38. Schulte-Mattler WJ, Krack P. Treatment of chronic tension-type headache with botulinum toxin A: a randomized, double-blind, placebo-controlled multicenter study. Pain 2004 May;109(1-2):110-4
39. Silberstein SD, Gobel H, Jensen R, et al. Botulinum toxin type A in the prophylactic treatment of chronic tension-type headache: a multicentre, doubleblind, randomized, placebo-controlled, parallel-group study. Cephalalgia 2006 Jul;26(7):790-800
40. Straube A, Empl M, Ceballos-Baumann A, et al. Pericranial injection of botulinum toxin type A (Dysport) for tension-type headache-a multicentre, double-blind, randomized, placebo-controlled study. Eur J Neurol 2008 Mar;15(3):205-13
41. Harden RN, Cottrill J, Gagnon CM, et al. Botulinum toxin a in the treatment of chronic tension-type headache with cervical myofascial trigger points: a randomized, double-blind, placebo-controlled pilot study. Headache 2009 May;49(5):732-43
42. Knoderer WR. Botulinum toxin type A for treating co-morbid migraines/headaches and TMP symptoms [abstract no. PO398]. Cephalalgia 2009; 29 Suppl. 1
43. Gobel H, Heinze A, Reichel G, et al. Efficacy and safety of a single botulinum type A toxin complex treatment (Dysport) for the relief of upper back myofascial pain syndrome: results from a randomized double-blind placebocontrolled multicentre study. Pain 2006 Nov;125(1-2):82-8
44. Freund BJ, Schwartz M. Treatment of whiplash associated neck pain [corrected] with botulinum toxin-A: a pilot study. J Rheumatol 2000 Feb;27(2):481-4
45. Wheeler AH, Goolkasian P, Gretz SS. A randomized, double-blind, prospective pilot study of botulinum toxin injection for refractory, unilateral, cervicothoracic, paraspinal, myofascial pain syndrome. Spine (Phila Pa 1976) 1998 Aug. 1;23(15):1662-6; discussion 7
46. Ferrante FM, Bearn L, Rothrock R, et al. Evidence against trigger point injection technique for the treatment of cervicothoracic myofascial pain with botulinum toxin type A. Anesthesiology 2005 Aug;103(2):377-83
47. Ojala T, Arokoski JP, Partanen J. The effect of small doses of botulinum toxin a on neck-shoulder myofascial pain syndrome: a double-blind, randomized, and controlled crossover trial. Clin J Pain 2006 Jan;22(1):90-6
48. Qerama E, Fuglsang-Frederiksen A, Kasch H, et al. A double-blind, controlled study of botulinum toxin A in chronic myofascial pain. Neurology 2006 Jul. 25;67(2):241-5
49. Lew HL, Lee EH, Castaneda A, et al. Therapeutic use of botulinum toxin type A in treating neck and upper-back pain of myofascial origin: a pilot study. Arch Phys Med Rehabil 2008 Jan;89(1):75-80
50. Foster L, Clapp L, Erickson M, et al. Botulinum toxin A and chronic low back pain: a randomized, double-blindstudy. Neurology 2001 May 22;56(10):1290-3
51. Singh JA, Mahowald ML, Noorbaloochi S. Intra-articular botulinum toxin A for refractory shoulder pain: a randomized, double-blinded, placebocontrolled trial. Transl Res 2009 May;153(5):205-16
52. Ranoux D, Attal N, Morain F, et al. Botulinum toxin type A induces direct analgesic effects in chronic neuropathic pain. Ann Neurol 2008 Sep;64(3):274-83
53. Yuan RY, Sheu JJ, Yu JM, et al. Botulinum toxin for diabetic neuropathic pain: a randomized double-blind crossover trial. Neurology 2009 Apr. 28;72(17):1473-8
54. Abbott JA, Jarvis SK, Lyons SD, et al. Botulinum toxin type A for chronic pain and pelvic floor spasm in women: a randomized controlled trial. Obstet Gynecol 2006 Oct;108(4):915-23
55. Childers MK, Wilson DJ, Gnatz SM, et al. Botulinum toxin type A use in piriformis muscle syndrome: a pilot study. Am J Phys Med Rehabil 2002 Oct;81(10):751-9
56. Fishman LM, Anderson C, Rosner B. BOTOX and physical therapy in the treatment of piriformis syndrome. Am J Phys Med Rehabil 2002 Dec;81(12):936-42
57. Seo MW, Lim MH. Primary pain on the vertex: successful treatment with botulinum toxin A [abstract no. PO256]. Cephalalgia 2009; 29 Suppl. 1
58. Yelnik AP, Colle FM, Bonan IV, et al. Treatment of shoulder pain in spastic hemiplegia by reducing spasticity of the subscapular muscle: a randomised, double blind, placebo controlled study of botulinum toxin A. J Neurol Neurosurg Psychiatry 2007 Aug;78(8):845-8
59. Edlund W, Gronseth G, So Y, et al. Clinical practice guideline process manual. St Paul (MN): American Academy of Neurology, 2004
60. Foster KA. A new wrinkle on pain relief: re-engineering clostridial neurotoxins for analgesics. Drug Discov Today 2005 Apr. 15;10(8):563-9
61. Mense S. Neurobiological basis for the use of botulinum toxin in pain therapy. J Neurol 2004 Feb; 251 Suppl. 1: I1-7
62. Burnstock G. P2X receptors in sensory neurones. Br J Anaesth 2000 Apr;84(4):476-88
63. Fagerlund MJ, Eriksson LI. Current concepts in neuromuscular transmission. Br J Anaesth 2009 Jul;103(1):108-14
64. Yoon TY, Shin YK. Progress in understanding the neuronal SNARE function and its regulation. Cell Mol Life Sci 2009 Feb;66(3):460-9
65. Poulain B, Popoff MR, Molgo J. How do the botulinum neurotoxins block neurotransmitter release: from botulism to the molecular mechanism of action. Botulinum J 2008;1(1):14-87
66. Dong M, Liu H, Tepp WH, et al. Glycosylated SV2A and SV2B mediate the entry of botulinum neurotoxin E into neurons. Mol Biol Cell 2008 Dec;19(12):5226-37
67. Binz T, Rummel A. Cell entry strategy of clostridial neurotoxins. J Neurochem 2009 Jun;109(6):1584-95
68. Silvaggi NR, Wilson D, Tzipori S, et al. Catalytic features of the botulinum neurotoxin A light chain revealed by high resolution structure of an inhibitory peptide complex. Biochemistry 2008 May 27;47(21):5736-45
69. Keller JE, Neale EA. The role of the synaptic protein snap-25 in the potency of botulinum neurotoxin type A. J Biol Chem 2001 Apr. 20;276(16):13476-82
70. Casale R, Tugnoli V. Botulinum toxin for pain. Drugs R D 2008;9(1):11-27
71. Aoki KR. Review of a proposed mechanism for the antinociceptive action of botulinum toxin type A. Neurotoxicology 2005 Oct;26(5):785-93
72. Hackett R, Kam PC. Botulinum toxin: pharmacology and clinical developments: a literature review. Med Chem 2007 Jul;3(4):333-45
73. Lucioni A, Bales GT, Lotan TL, et al. Botulinum toxin type A inhibits sensory neuropeptide release in rat bladder models of acute injury and chronic inflammation. BJU Int 2008 Feb;101(3):366-70
74. Purkiss J, Welch M, Doward S, et al. Capsaicin-stimulated release of substance P from cultured dorsal root ganglion neurons: involvement of two distinct mechanisms. Biochem Pharmacol 2000 Jun. 1;59(11):1403-6
75. Meng J, Wang J, Lawrence G, et al. Synaptobrevin I mediates exocytosis of CGRP from sensory neurons and inhibition by botulinum toxins reflects their anti-nociceptive potential. J Cell Sci 2007 Aug. 15; 120 (Pt 16):2864-74
76. Cui M, Khanijou S, Rubino J, et al. Subcutaneous administration of botulinum toxin A reduces formalin-induced pain. Pain 2004 Jan;107(1-2):125-33
77. Luvisetto S, Marinelli S, Cobianchi S, et al. Anti-allodynic efficacy of botulinum neurotoxin A in a model of neuropathic pain. Neuroscience 2007 Mar. 2;145(1):1-4
78. Luvisetto S, Marinelli S, Lucchetti F, et al. Botulinum neurotoxins and formalin-induced pain: central vs. peripheral effects in mice. Brain Res 2006 Apr. 12;1082(1):124-31
79. Park HJ, Lee Y, Lee J, et al. The effects of botulinum toxin A on mechanical and cold allodynia in a rat model of neuropathic pain. Can J Anaesth 2006 May;53(5):470-7
80. Kramer HH, Angerer C, Erbguth F, et al. Botulinum Toxin A reduces neurogenic flare but has almost no effect on pain and hyperalgesia in human skin. J Neurol 2003 Feb;250(2):188-93
81. Sycha T, Samal D, Chizh B, et al. A lack of antinociceptive or antiinflammatory effect of botulinum toxin A in an inflammatory human pain model. Anesth Analg 2006 Feb;102(2):509-16
82. Gazerani P, Staahl C, Drewes AM, et al. The effects of botulinum toxin type A on capsaicin-evoked pain, flare, and secondary hyperalgesia in an experimental human model of trigeminal sensitization. Pain 2006 Jun;122(3):315-25
83. Tugnoli V, Capone JG, Eleopra R, et al. Botulinum toxin type A reduces capsaicin-evoked pain and neurogenic vasodilatation in human skin. Pain 2007 Jul;130(1-2):76-83
84. Voller B, Sycha T, Gustorff B, et al. A randomized, double-blind, placebo controlled study on analgesic effects of botulinum toxin A. Neurology 2003 Oct. 14;61(7):940-4
85. Blersch W, Schulte-Mattler WJ, Przywara S, et al. Botulinum toxin A and the cutaneous nociception in humans: a prospective, double-blind, placebocontrolled, randomized study. J Neurol Sci 2002 Dec. 15;205(1):59-63
86. Foster KA. Engineered toxins: new therapeutics. Toxicon 2009;54(5):587-92
87. Bonifacino JS, Glick BS. The mechanisms of vesicle budding and fusion. Cell 2004 Jan 23;116(2):153-66
88. Sutton JM, Wayne J, Scott-Tucker A, et al. Preparation of specifically activatable endopeptidase derivatives of Clostridium botulinum toxins type A, B, and C and their applications. Protein Expr Purif 2005 Mar;40(1):31-41
89. Chaddock JA, Purkiss JR, Friis LM, et al. Inhibition of vesicular secretion in both neuronal and nonneuronal cells by a retargeted endopeptidase derivative of Clostridium botulinum neurotoxin type A. Infect Immun 2000 May;68(5):2587-93
90. Chaddock JA, Purkiss JR, Duggan MJ, et al. A conjugate composed of nerve growth factor coupled to a non-toxic derivative of Clostridium botulinum neurotoxin type A can inhibit neurotransmitter release in vitro. Growth Factors 2000;18(2):147-55
91. Duggan MJ, Quinn CP, Chaddock JA, et al. Inhibition of release of neurotransmitters from rat dorsal root ganglia by a novel conjugate of a Clostridium botulinum toxin A endopeptidase fragment and Erythrina cristagalli lectin. J Biol Chem 2002 Sep. 20;277(38):34846-52
92. Chaddock JA, Purkiss JR, Alexander FC, et al. Retargeted clostridial endopeptidases: inhibition of nociceptive neurotransmitter release in vitro, and antinociceptive activity in in vivo models of pain. Mov Disord 2004 Mar; 19 Suppl. 8: S42-7
93. Product pipeline overview. Abingdon: Syntaxin [online]. Available from URL: http://www.syntaxin. com/biopharmaceutical-product-pipeline.php [Accessed 2010 Mar. 24]
94. Pipeline. Irvine (CA): Allergan [online]. Available from URL: http://www.allergan. com/research-and-development/pipeline.htm [Accessed 2010 Mar. 24]
95. Chen S, Barbieri JT. Unique substrate recognition by botulinum neurotoxins serotypes A and E. J Biol Chem 2006 Apr. 21;281(16):10906-11
96. Chen S, Barbieri JT. Engineering botulinum neurotoxin to extend therapeutic intervention. Proc Natl Acad Sci U S A 2009 Jun. 9;106(23):9180-4